GE sells biopharma business to Danaher for $21.4B, reconsiders healthcare IPO – Becker's Hospital Review

GE sells biopharma business to Danaher for .4B, reconsiders healthcare IPO – Becker's Hospital Review

GE sells biopharma business to Danaher for $21.4B, reconsiders healthcare IPO  Becker’s Hospital Review

GE’s biopharma business, which provides tools to support biopharmaceutical research and development, brought in roughly $3 billion in revenue in 2018.

GE sells biopharma business to Danaher for .4B, reconsiders healthcare IPO – Becker's Hospital Review